Immuneering Corp (IMRX)
1.47
0.00 (0.00%)
USD |
NASDAQ |
May 20, 16:00
1.48
+0.01
(+0.68%)
After-Hours: 20:00
Immuneering Cash from Investing (Quarterly): 21.39M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.39M |
| December 31, 2023 | 3.133M |
| September 30, 2023 | -23.97M |
| June 30, 2023 | 9.163M |
| March 31, 2023 | 18.97M |
| December 31, 2022 | 8.152M |
| September 30, 2022 | -0.8801M |
| June 30, 2022 | 22.15M |
| March 31, 2022 | 12.40M |
| Date | Value |
|---|---|
| December 31, 2021 | -22.81M |
| September 30, 2021 | -52.77M |
| June 30, 2021 | -0.0198M |
| March 31, 2021 | -0.0166M |
| December 31, 2020 | -0.0381M |
| September 30, 2020 | -0.0056M |
| June 30, 2020 | -0.0054M |
| March 31, 2020 | -0.0043M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-52.77M
Minimum
Sep 2021
22.15M
Maximum
Jun 2022
-0.3029M
Average
-0.0054M
Median
Jun 2020
Cash from Investing (Quarterly) Benchmarks
| Geron Corp | 34.21M |
| SELLAS Life Sciences Group Inc | -- |
| Elicio Therapeutics Inc | 0.003M |
| ADMA Biologics Inc | -2.362M |
| Outlook Therapeutics Inc | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -15.49M |
| Cash from Financing (Quarterly) | 0.9799M |
| Free Cash Flow | -50.39M |
| Free Cash Flow Per Share (Quarterly) | -0.5287 |
| Free Cash Flow Yield | -117.6% |